5300-03-8
基本信息
异维A酸杂质4
9-顺式维甲酸
9-顺式视黄酸
9-CIS维甲酸
维A酸EP杂质D
9-顺式视黄醇酸
异维A酸EP杂质D
异维甲酸EP杂质D
9-顺-视黄酸 [干冰运输,需加收额外费用]
物理化学性质
熔点 | 189-191°C |
沸点 | 462.8±14.0 °C(Predicted) |
密度 | 1.011±0.06 g/cm3(Predicted) |
RTECS号 | VH6450000 |
储存条件 | −20°C |
溶解度 | 可溶于乙腈(非常轻微)、氯仿(轻微)、DMSO(轻微)、乙醇 |
酸度系数(pKa) | 4.73±0.33(Predicted) |
形态 | 淡黄色至橙色结晶性粉末。 |
颜色 | 淡黄色至黄色 |
水溶解性 | Soluble in chloroform (50 mg/ml), DMSO (~25 mg/ml), ethanol (25 mg/ml), and acetone (25 mg/ml). Insoluble in water. |
敏感性 | Moisture & Light Sensitive |
稳定性 | Store Dry in Freezer at -20°C for up to 1 year; in Solution at -20°C for up to 3 Months. |
CAS 数据库 | 5300-03-8(CAS DataBase Reference) |
安全数据
危险性符号(GHS) | GHS07,GHS08 |
警示词 | 危险 |
危险性描述 | H315-H319-H335-H360 |
防范说明 | P201-P302+P352-P305+P351+P338-P308+P313 |
危险品标志 | T |
危险类别码 | R61-R36/37/38 |
安全说明 | S53-S26-S36/37/39-S45 |
WGK Germany | 3 |
海关编码 | 29162090 |
毒害物质数据 | 5300-03-8(Hazardous Substances Data) |
常见问题列表
异维A酸EP杂质D是异维A酸合成过程中产生产生的杂质,又名阿利维甲酸,是治疗皮肤病领域的重要药物,是全反式维甲酸(式II,化学名:3,7-二甲基-9-(2,6,6-三甲基环己烯-1-基)-2E,4E,6E,8E-全反式壬四烯酸)的9-顺异构体。
异维A酸EP杂质D(式I化合物)的制备:在氮气保护下,往反应瓶中加入乙醇2L、全反式维甲酸100g,搅拌,然后升温至50~55℃,加入PdCl289mg。反应1.5h后,经HPLC检测产物纯度为21%。反应液缓慢降温至0~5℃,保温180分钟,抽滤;滤液加入另一干净反应瓶中,继续降温至-10~-6℃,保温20分钟,抽滤,得到产物异维A酸EP杂质D 12.1g,总收率12.1%,HPLC纯度99.60%。以全反式维甲酸为原料,采用钯化合物催化,在普通的工业级有机溶剂中可得到阿利维甲酸。方法操作简便,成本低,条件可控,便于工业生产;经过后处理步骤后,可得到纯度99%以上的阿利维甲酸,产物收率达到12%以上,具有较高的应用价值。
9-cis-Retinoic acid (1-10 μM; 0-5 days; CA 9-22 and NA cells) treatment significantly decreases proliferation in a dose-dependent manner in CA 9-22 and NA cells.
9-cis-Retinoic acid (1 μM; 24 hours) treatment significantly increases PPARγ functional activity by >200% in CA 9-22 and NA aerodigestive cells.
9-cis-Retinoic acid treatment results in the formation of a nuclear PPARγ-RXRα heterodimer supershift complex in CA 9-22 cells.
9-cis-Retinoic acid inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma (CTCL) in a dose-dependent and time-dependent manner. 9-cis-Retinoic acid also induces G0/G1 cell cycle arrest by downregulation of cyclin D1. 9-cis-Retinoic acid significantly decreases phosphorylation of JAK1, STAT3, and STAT5 and downregulated Bcl-xL and cyclin D1.
Cell Proliferation Assay
Cell Line: | CA 9-22 and NA cells |
Concentration: | 1 μM, 10 μM |
Incubation Time: | 0 day, 1 day, 3 days, 5 days |
Result: | Significantly decreased proliferation. |
9-cis-Retinoic acid (1 mg/kg; intravenous injection; daily; for 10 days; male C57BL/6J mice) treatment significantly decreases the serum ALT and AST level, alleviates hepatic necrosis of the bile duct ligation (BDL)-mice.
Animal Model: | Male C57BL/6J mice (6-8 weeks; 19-22 g) treatment with bile duct ligated |
Dosage: | 1 mg/kg |
Administration: | Intravenous injection; daily; for 10 days |
Result: | Significantly decreased the serum ALT and AST level, alleviated hepatic necrosis. |